Gary Pace Buys 30,000 Shares of Cardiff Oncology (NASDAQ:CRDF) Stock

Cardiff Oncology, Inc. (NASDAQ:CRDF) Director Gary Pace purchased 30,000 shares of the stock in a transaction that occurred on Thursday, June 18th. The stock was bought at an average cost of $1.22 per share, with a total value of $36,600.00. Following the acquisition, the director owned 1,356,376 shares of the company’s stock, valued at $1,654,778.72. This represents a 2.26% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Cardiff Oncology Stock Performance

NASDAQ:CRDF opened at $1.26 on Wednesday. The stock’s fifty day moving average price is $1.61 and its two-hundred day moving average price is $1.96. Cardiff Oncology, Inc. has a 52-week low of $1.16 and a 52-week high of $4.55. The company has a market cap of $86.15 million, a price-to-earnings ratio of -1.88 and a beta of 1.36.

Cardiff Oncology (NASDAQ:CRDF) last released its earnings results on Thursday, May 14th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.05). Cardiff Oncology had a negative net margin of 8,527.43% and a negative return on equity of 95.51%. The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.09 million. On average, equities analysts predict that Cardiff Oncology, Inc. will post -0.66 EPS for the current fiscal year.

Institutional Trading of Cardiff Oncology

A number of hedge funds have recently modified their holdings of CRDF. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Cardiff Oncology by 50.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,319 shares of the company’s stock valued at $108,000 after acquiring an additional 11,497 shares during the period. Rhumbline Advisers raised its holdings in shares of Cardiff Oncology by 18.8% in the 1st quarter. Rhumbline Advisers now owns 63,142 shares of the company’s stock valued at $198,000 after purchasing an additional 9,970 shares during the period. Geode Capital Management LLC lifted its stake in Cardiff Oncology by 7.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock valued at $4,723,000 after purchasing an additional 104,409 shares during the last quarter. Invesco Ltd. grew its holdings in Cardiff Oncology by 24.9% during the second quarter. Invesco Ltd. now owns 23,795 shares of the company’s stock worth $75,000 after purchasing an additional 4,749 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in Cardiff Oncology by 23.9% during the second quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company’s stock worth $69,000 after purchasing an additional 4,232 shares during the period. 16.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Piper Sandler lowered their price target on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Wall Street Zen lowered shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. TD Cowen cut shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a research note on Monday, June 1st. HC Wainwright lowered shares of Cardiff Oncology from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Finally, Craig Hallum cut shares of Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 target price for the company. in a research report on Wednesday, June 3rd. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Cardiff Oncology presently has a consensus rating of “Hold” and a consensus target price of $9.80.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.